Whilst it may not be a huge deal, we thought it was good to see that the The Oncology Institute, Inc. (NASDAQ:TOI) Chief Operating Officer, Matthew Miller, recently bought US$70k worth of stock, for US$0.95 per share. Even though that isn't a massive buy, it did increase their holding by 143%, which is arguably a good sign.

See our latest analysis for Oncology Institute

Oncology Institute Insider Transactions Over The Last Year

In the last twelve months, the biggest single sale by an insider was when the Founder & Chief Clinical Officer, Richy Agajanian, sold US$9.6m worth of shares at a price of US$6.00 per share. While we don't usually like to see insider selling, it's more concerning if the sales take place at a lower price. The silver lining is that this sell-down took place above the latest price (US$1.60). So it is hard to draw any strong conclusion from it.

In total, Oncology Institute insiders sold more than they bought over the last year. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

I will like Oncology Institute better if I see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.

Does Oncology Institute Boast High Insider Ownership?

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. It appears that Oncology Institute insiders own 24% of the company, worth about US$28m. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.

What Might The Insider Transactions At Oncology Institute Tell Us?

Insider purchases may have been minimal, in the last three months, but there was no selling at all. That said, the purchases were not large. Recent sales exacerbate our caution arising from analysis of Oncology Institute insider transactions. But we do like the fact that insiders own a fair chunk of the company. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Oncology Institute. To help with this, we've discovered 3 warning signs (2 can't be ignored!) that you ought to be aware of before buying any shares in Oncology Institute.

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.